South Korea Ophthalmic Drugs Market Research Report By Dosage Form (Eye Drops, Eye Ointments, Eye Solutions, Gels, Capsules Tablets, Others), By Product Type (Prescription Drug, OTC Drug), By Drug Class (Antibiotics, Anti-Inflammatory, Anti-Glaucoma, Others), By Indication (Glaucoma, Retinal Disorder, Dry Eye, Eye Allergy, Others) and By Distribution Channels (Hospital pharmacies, Drug stores, Online pharmacies, Others) -Forecast to 2035
The South Korea Ophthalmic Drugs Market is projected to grow from 748 USD Million in 2024 to 1496 USD Million by 2035.
South Korea Ophthalmic Drugs Market Key Trends and Highlights
| 2024 Market Size | 748 (USD Million) |
| 2035 Market Size | 1496 (USD Million) |
| CAGR (2025-2035) | 6.5% |
iSUN Pharma, Hanmi Pharmaceutical, Chong Kun Dang, AhnGook Pharmaceutical, Sungwun Pharmaceutical, Genexine, Myungmoon Pharmaceutical, Kyung Dong Pharmaceutical, Hugel, Daewoong Pharmaceutical, LG Chem, Medytox, DongA ST, Samsung Bioepis, Korea United Pharm
Our Impact
Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals
Partnering with 2000+ Global Organizations Each Year
30K+ Citations by Top-Tier Firms in the Industry
In the South Korea Ophthalmic Drugs Market, there has been a notable shift towards innovative therapies, particularly in the realm of dry eye syndrome and age-related macular degeneration. The increase in the elderly population, a significant demographic in South Korea, is driving demand for effective treatments. Furthermore, the rise in digital device usage has contributed to a growing prevalence of vision-related issues, thereby escalating the need for ophthalmic medications. South Korea's government is actively promoting research and development initiatives, providing support for local pharmaceutical companies to advance their drug development capabilities.
There are also promising opportunities in the biotechnology sector for the development of novel ophthalmic drugs. With local companies increasingly focusing on biopharmaceuticals, there is potential for breakthroughs in targeted therapies and personalized medicine for ocular conditions. South Korea's strategic position in the Asia-Pacific region allows for collaboration and partnership opportunities with global pharmaceutical firms, enhancing access to advanced technologies and expertise. In recent times, a trend towards digital health solutions has emerged, with telemedicine and digital platforms offering patients easier access to eye care specialists.
The future landscape of the ophthalmic drugs market is leaning towards integrated healthcare solutions, combining traditional therapies with technological innovations. This can lead to improved patient compliance and outcomes, ultimately benefiting the healthcare system in South Korea. The ongoing efforts to enhance patient education and raise awareness about eye health further contribute to the positive momentum within this market, aligning with national health objectives to reduce the burden of ocular diseases.
The South Korea ophthalmic drugs market is witnessing increasing adoption of targeted therapies and sustained-release drug delivery systems designed to improve treatment outcomes and patient adherence. Pharmaceutical companies are developing advanced ophthalmic formulations, including preservative-free eye drops, intravitreal injections, biodegradable implants, and extended-release therapies for glaucoma, retinal diseases, dry eye syndrome, and inflammatory eye disorders. These innovations reduce dosing frequency while enhancing therapeutic effectiveness and patient convenience. Continuous investments in ophthalmic pharmaceutical research and South Korea's advanced healthcare infrastructure are accelerating the adoption of next-generation ophthalmic drugs across hospitals and specialty eye care clinics.
The growing prevalence of age-related eye disorders is emerging as a key trend in the South Korea ophthalmic drugs market. Increasing cases of glaucoma, cataracts, diabetic retinopathy, age-related macular degeneration, and dry eye disease are driving demand for innovative pharmaceutical therapies that preserve vision and improve long-term disease management. Healthcare providers are increasingly adopting personalized treatment approaches supported by early diagnosis and advanced ophthalmic medications. In addition, rising healthcare expenditure, greater awareness of preventive eye care, and continuous expansion of specialty ophthalmology services are expected to support sustained growth in the South Korea ophthalmic drugs market throughout the forecast period.
The South Korea Ophthalmic Drugs Market is expected to experience notable growth, particularly within the dosage form segment, which plays a critical role in effective treatment delivery for various eye disorders. Eye drops have become a widely accepted form of medication delivery in ophthalmology, primarily due to their ease of administration and direct contact with ocular tissues, making them a favorite among patients and healthcare professionals alike.
Meanwhile, eye ointments, with their longer retention time on the eye surface, cater to specific needs such as lubrication and protection against moisture loss, providing an important alternative for more severe conditions.Eye solutions are also gaining traction as a versatile dosage form, especially in cases requiring a sterile and homogeneous fluid for systemic absorption or localized therapy, while gels present a unique proposition owing to their mucoadhesive properties that enhance the drug’s residence time on the ocular surface, thus improving therapeutic outcomes.
The rise of capsules and tablets, although less common in the direct treatment of eye diseases, marks a noticeable trend towards systemic treatment approaches, which can address underlying conditions that affect ocular health.Overall, the segmentation within the South Korea Ophthalmic Drugs Market data indicates a dynamic landscape driven by patient preference, innovation in drug formulation, and ongoing advancements in ophthalmic technology, fostering an environment ripe for new product development and enhanced treatment methodologies.
The South Korea Ophthalmic Drugs Market demonstrates a structured segmentation primarily focused on Product Type, which comprises Prescription Drugs and OTC Drugs. The Prescription Drugs segment remains crucial, addressing a variety of complex eye conditions and disorders, thereby ensuring a significant share of market activity due to the increasing prevalence of ocular diseases. In South Korea, a rising aging population contributes to the demand for effective prescription treatments, driving innovations and advancements within this segment.
On the other hand, the OTC Drugs segment caters to a growing consumer base seeking convenient solutions for common eye ailments such as dryness and irritation. The increasing awareness of eye care and self-medication trends considerably boosts the OTC market, reflecting a dynamic shift in consumer behavior towards eye health. Both segments are shaped by the need for accessibility and efficacy in treatments, making them integral to the overall landscape of the South Korea Ophthalmic Drugs Market.
Furthermore, the regulatory framework provided by governmental organizations supports innovation and growth within these product types, positioning South Korea as a significant player in the ophthalmic therapeutics landscape.Overall, the diverse needs of the population dictate the ongoing evolution within these segments, leading to potential growth opportunities in the market.
The South Korea Ophthalmic Drugs Market is intricately segmented into various drug classes that cater to specific ocular health needs. Among these, Antibiotics play a crucial role in addressing bacterial infections, which are prevalent in patients undergoing eye surgeries or suffering from conditions like conjunctivitis. The Anti-Inflammatory category is significant as it is widely used for treating conditions such as allergic conjunctivitis and post-operative inflammation, enhancing post-surgical recovery outcomes. The Anti-Glaucoma segment is vital due to the increasing prevalence of glaucoma, a leading cause of blindness in South Korea, driving demand for effective treatment options.
In addition, the 'Others' category encapsulates alternative medications that provide holistic treatment approaches, supporting the diverse array of ocular disorders faced by patients. As the population ages, the demand for these ophthalmic drug classes is expected to grow, making this segment a focal point for R and market expansion strategies. Overall, the South Korea Ophthalmic Drugs Market reflects a dynamic landscape driven by therapeutic needs, increasing disease awareness, and technological advancements in drug formulation.
The South Korea Ophthalmic Drugs Market segmentation by indication includes various critical areas such as Glaucoma, Retinal Disorder, Dry Eye, Eye Allergy treatment, among others. Glaucoma, being one of the leading causes of blindness, drives substantial demand for effective treatments, emphasizing the importance of ongoing advancements in this sector. Retinal disorders are increasingly prevalent, fuelled by the aging population and rising incidence of diabetes, creating a significant need for innovative therapies.
The Dry Eye segment is gaining traction with the rise in screen time and environmental factors impacting eye health, showcasing the urgency for targeted solutions.Eye allergies also represent a noteworthy category, driven by increased exposure to allergens in urban environments, thus calling for effective management options. Each of these indications contributes significantly to the overall South Korea Ophthalmic Drugs Market revenue, driven by a growing awareness about eye health and emerging treatment options. Moreover, these segments face growth opportunities propelled by technological innovations and an expanding healthcare infrastructure.
The dynamically evolving landscape of the South Korea Ophthalmic Drugs Market data indicates a robust interplay of growth drivers and the pressing need for effective ophthalmic solutions.
The South Korea Ophthalmic Drugs Market showcases a diverse array of Distribution Channels that play a vital role in ensuring the accessibility of ophthalmic medications. Hospital pharmacies remain a key component, especially due to their integrated approach within healthcare systems, providing specialized care for patients undergoing treatment. Drug stores also hold significant importance, serving as convenient access points for patients seeking over-the-counter and prescription medications for eye health. The rise of online pharmacies has transformed the way patients procure their eye medications, offering convenience and accessibility, particularly for those in remote areas or with mobility issues.
This segment is increasingly gaining traction as digital health adoption grows among the population. Additionally, the category labeled as "Others," encompassing specialty clinics and healthcare institutions, contributes to fulfilling niche market needs that may not be as broadly addressed by larger channels. In understanding the market segmentation for the South Korea Ophthalmic Drugs Market, it is evident that these Distribution Channels are not only critical for enhancing patient access but also play a significant role in addressing varying consumer preferences and the evolving landscape of healthcare in the country.
Get more detailed insights about South Korea Ophthalmic Drugs Market Request Free Sample
The South Korea Ophthalmic Drugs Market is characterized by a dynamic competitive landscape driven by the increasing prevalence of ocular diseases such as glaucoma, age-related macular degeneration, and diabetic retinopathy. The market is marked by a strong emphasis on innovation and the development of advanced therapies aimed at addressing unmet medical needs in eye health. Key players are continually investing in research and development to enhance their product offerings, with a focus on formulations that provide better efficacy and safety profiles. The competitive insights reveal a growing trend toward collaboration and strategic partnerships among firms as companies seek to expand their market share, enhance their product pipelines, and leverage synergies in manufacturing and marketing. The presence of well-established domestic players alongside international pharmaceutical giants adds to the complexity of the market, resulting in a diverse array of treatment options for patients.iSUN Pharma is a notable player within the South Korea Ophthalmic Drugs Market, focusing on developing innovative therapies for various ocular conditions. The company has established a strong market presence through its robust product pipeline, which includes a range of ophthalmic formulations that cater to the needs of healthcare professionals and patients alike. The strengths of iSUN Pharma lie in its commitment to research and development, allowing the company to keep pace with advancements in the field. Its strategic collaborations with research institutions and other healthcare entities further bolster its position, enabling access to cutting-edge technology and expertise. Additionally, iSUN Pharma's efficient distribution networks and strong relationships with healthcare providers enhance its market visibility and result in a solid reputation among ophthalmologists and patients.Hanmi Pharmaceutical has also carved a significant niche within the South Korea Ophthalmic Drugs Market, which is recognized for its comprehensive portfolio that addresses various eye disorders. The company boasts several key products and services that cater to diverse ocular conditions, contributing to a solid market presence. Hanmi Pharmaceutical's strengths include its commitment to innovation and the development of proprietary formulations aimed at improving therapeutic outcomes for patients. The company has conducted strategic mergers and acquisitions to strengthen its capabilities and expand its footprint within the ophthalmic segment. These initiatives have not only enriched its product offerings but also positioned Hanmi Pharmaceutical as a key competitor in the market, with a focus on integrating cutting-edge research and enhancing patient access to high-quality ophthalmic treatments.
In South Korea, the ophthalmic drugs market has experienced notable developments recently, reflecting a dynamic landscape in the healthcare sector. A significant occurrence in March 2023 was the collaboration between Hanmi Pharmaceutical and Genexine, focusing on the development of new ophthalmic formulations, which underscores a trend toward innovative therapeutic solutions. Furthermore, iSUN Pharma has launched a new eye drop product aimed at treating dry eye syndrome, marking an expansion of its portfolio and increasing competition in the market.
The growth in market valuation for companies such as LG Chem and Hugel has been propelled by increased demand for advanced ophthalmic treatments, especially those targeting conditions like glaucoma and retinal diseases. The government's efforts in bolstering pharmaceutical innovation through support programs have also accelerated advancements within the sector. Additionally, mergers and acquisitions remain a focal point, with Chong Kun Dang acquiring a key stake in a niche biotechnology firm in June 2023 to enhance its ophthalmic drug pipeline. The South Korean ophthalmic market is expected to continue evolving, driven by advancements in technology and increasing healthcare spending.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2023 | 703.54(USD Million) |
| MARKET SIZE 2024 | 748.0(USD Million) |
| MARKET SIZE 2035 | 1496.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.504% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Million |
| KEY COMPANIES PROFILED | iSUN Pharma, Hanmi Pharmaceutical, Chong Kun Dang, AhnGook Pharmaceutical, Sungwun Pharmaceutical, Genexine, Myungmoon Pharmaceutical, Kyung Dong Pharmaceutical, Hugel, Daewoong Pharmaceutical, LG Chem, Medytox, DongA ST, Samsung Bioepis, Korea United Pharm |
| SEGMENTS COVERED | Dosage Form, Product Type, Drug Class, Indication, Distribution Channels |
| KEY MARKET OPPORTUNITIES | Aging population healthcare needs, Rising prevalence of eye disorders, Advanced R&D capabilities, Growing demand for personalized medicine, Expansion of telemedicine services |
| KEY MARKET DYNAMICS | Aging population, Rising prevalence of eye diseases, Increasing healthcare expenditure, Advanced therapeutic innovations, Growing demand for personalized medicine |
| COUNTRIES COVERED | South Korea |
Kindly complete the form below to receive a free sample of this Report
“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”
“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”
“Thanks for sending the report it gives us a good global view of the Betaïne market.”
“Thank you, this will be very helpful for OQS.”
“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”
“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”
“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”
“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”
“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”
